Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Trial details
- Registry ID
- NCT03533257
- Phase
- Phase 2
The PDUFA goal date for AMX0035 (Proprietary formulation of taurursodiol and sodium phenylbutyrate) in treatment of ALS was in Sep 2022, as disclosed by Amylyx Pharmaceuticals Inc. (AMLX).
Drug identity checked against registry records
Also recorded as Proprietary formulation of taurursodiol and sodium phenylbutyrate; RELYVRIO; Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO, also known as Ursodoxicoltaurine or Tauroursodeoxycholic Acid [TUDCA]); Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO; also known as Tauroursodeoxycholic Acid [TUDCA])
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseNCT03533257 | AMLX | Phase 2 | Completed | 2020-10-22Actual |
| AMX0035 and Progressive Supranuclear PalsyNCT06122662 | AMLX | Phase 2, Phase 3 | Completed | 2025-09-30Actual |
| Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentNCT05021536 | AMLX | Phase 3 | Unknown | 2024-01-19Actual |
| AMX0035 in Adult Patients With Wolfram SyndromeNCT05676034 | AMLX | Phase 2 | Active not recruiting | 2024-07-23Actual |
| AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03127514 | AMLX | Phase 2 | Completed | 2019-09-25Actual |
| Open Label Extension Study of AMX0035 in Patients With ALSNCT03488524 | AMLX | Phase 2 | Completed | 2021-03-01Actual |
| Extension Study Evaluating The Safety And Tolerability of AMX0035NCT05619783 | AMLX | Phase 3 | Completed | 2024-10-16Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-09Month | AMX0035Amylyx Pharmaceuticals Inc. · AMLX | Company-disclosed PDUFA goal dateAnnounced review target | treatment of ALS | Open original sourceRead source excerptthe FDA originally set the PDUFA date for AMX0035 for the treatment of ALS, for June 29, 2022, and then extended the review timeline for our NDA to September 2022 First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026 |